Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Gluten-Free Diet

Gluten-Free Diet

The gluten-free diet is a dietary regimen that avoids foods containing gluten, a protein found in wheat, barley, and rye.
This diet is primarly used to manage celiac disease, a condition where the immune system reacts abnormaly to gluten, causing damage to the small intestines.
Adhering to a gluten-free diet can help reduce symptoms and prevent long-term complications in those with celiac disease.
The diet may also be prescribed for non-celiac gluten sensitivuty, where individuals experience gastrointestinal distress after consuming gluten-containing foods.
Carefully following a gluten-free diet, which requires avoiding breads, pastas, cereals, and many processed foods, is essential for maintaining intestinal health and nutrient absorption in those with gluten-related disorders.

Most cited protocols related to «Gluten-Free Diet»

1
Celiac Disease Serum Antibody Workshop
Cited 13 times
Six laboratories contributed sera (2 ml) from individuals with CD as defined by accepted clinical criteria including small bowel biopsy, for the workshop: Liping Yu (University of Colorado), Claudio Tiberti (University of Rome), Daniel Agardh (Lund University), Markku Maki (University of Tampere), Olli Simell (University of Turku), and Ingrid van Hoogstraten (Vrije Universiteit Medical Center). One laboratory (Yu) contributed 20 samples, whereas the remaining 5 laboratories contributed a total of 21 samples. The healthy control sera were provided by Dr Patricia Mueller from the CDC, from individuals not known to have CD or type 1 diabetes. These control sera were originally used as negative controls for the Diabetes Antibody Standardization Program workshops, held in collaboration between the Immunology of Diabetes Society and the CDC (10 (link)). A total of 150 serum samples were distributed to each laboratory, with each laboratory receiving an equal aliquot (70–100 μl of serum) that was coded and blinded regarding clinical information, composed of 100 healthy control sera and 50 CD sera. The 50 CD sera included 30 samples from untreated patients, 11 samples from patients on a gluten-free diet (duration 2 months–2 years), 4 samples as replicates of one of the samples from the untreated patients, and 5 samples that were serial dilutions of one sample, at dilutions of 1:16, 1:32, 1:64, 1:128, and 1:256. Sera were diluted with sera from a healthy negative control sample. All sera were sent by express courier to each laboratory, with the sera randomized and coded 0 through 150. There was the potential for any sera in question to be sent back to a “reference” laboratory for testing, to control for any variables with shipping, but this was not needed during the study. Of the celiac sera, 28 samples were from children age 18 or less (the youngest was 3 years 9 months old), and 18 samples were from individuals also known to have type 1 diabetes.
Li M., Yu L., Tiberti C., Bonamico M., Taki I., Miao D., Murray J.A., Rewers M.J., Hoffenberg E.J., Agardh D., Mueller P., Stern M., Bonifacio E, & Liu E. (2009). A Report on the International Transglutaminase Autoantibody Workshop for Celiac Disease. The American journal of gastroenterology, 104(1), 154-163.
Publication 2009
ARID1A protein, human Biopsy Child Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Gluten-Free Diet Immunoglobulins Intestines, Small Patients Serum Technique, Dilution Workshops
2
Audit of Bread Nutrient Composition
Cited 8 times
An audit of bread was conducted using a recognised process for the collection of nutrient composition [30 (link)] from four major supermarkets in the Sydney Metropolitan area with the addition of a Bakery franchise (Bakers DelightTM, Camberwell, Victoria, Australia) during September 2017. Permission to visit each of the local supermarkets was sought prior to the audit process, and consent was requested from the store manager to proceed on the day of the audit (Woolworths, Neutral Bay; Independent Grocers of Australia (IGA), Cremorne; Coles, Neutral Bay; Aldi, North Sydney). Photographs were taken with smartphones of all available products within each bread category. Auditors captured all sides of the packets and ensured inclusion of any writing or logos including front-of-pack, nutrition information, the nutrition information panel (NIP) and health claims. Bread products included in this audit comprised of bread loaves; rolls; sandwich alternatives including wraps, thins, Lebanese and pita bread; as well as flatbreads such as Turkish, ciabatta, Indian, foccacia and yiros. Bakery breakfast products such as fruit bread, brioche, English muffins, crumpets and pancakes were also included. Loaf breads were categorised into three main types of bread loaves for analysis (white, wholemeal/whole grain and gluten-free options). Products excluded from this audit comprised of the store’s bakery goods section (in-store bakery), pizza bases, and bread sticks such as baguettes and breads containing added ingredients (e.g., olives and cheese). If products were sold out during the data collection period, auditors noted this and conducted an online search of the nutrition information on the manufacturer’s website. Product data from Bakers DelightTM were taken from their website as there is no nutritional information or claims made on the packaging supplied to consumers.
The information obtained from the photographs was entered into a Microsoft® Excel® spreadsheet (Version 2013, Redmond, Washington, USA). Information required for data entry included the NIP per serve and per 100 g, the percent of whole grains, ingredients and health-related claims (Table 1) including whole grain, dietary fibre, sodium, protein, carbohydrate and sugar and front-of-pack information (HSR). Additionally, the number of products eligible to make nutrition claims was documented. The eligibility of providing a whole grain content claim was assessed in line with The Code. The total number of products eligible for a claim was noted as well as the percentage of these that were eligible for each level (contains whole grain, high in whole grain and very high in whole grain) of claim. If any products registered or unregistered made a whole grain or nutrient claim that was not compliant with The Code or were deemed misleading, they were entered into a whole grain compliance monitoring document for follow up by GLNC.
Data were cross-checked with manufacturer data and following data entry, results were independently checked by a second reviewer for any inconsistencies or errors. Results were compared with data from the bread audit conducted by GLNC in 2014 [31 ] regarding change in sodium content and the number of whole grain products. This audit utilised the same methods and quality processes as the current audit, and collected a similar number of loaf breads (n = 242) and total breads (n = 474) from the same supermarket locations.
Grafenauer S, & Curtain F. (2018). An Audit of Australian Bread with a Focus on Loaf Breads and Whole Grain. Nutrients, 10(8), 1106.
Publication 2018
Bread Carbohydrates Cheese Dietary Fiber Eligibility Determination Fruit Gluten-Free Diet Nutrients Olives Proteins SELL protein, human Sodium Whole Grains
3
Coeliac Disease Cohort Study in Manitoba
Cited 7 times
Participants were recruited prospectively at the time of diagnosis of coeliac disease. In Manitoba, all testing for coeliac disease-associated antibodies is performed at a central laboratory. This facilitated a population-based approach to reduce recruitment bias. Specifically, a list of physicians with patients who tested positive for anti-tissue transglutaminase antibodies was generated on a weekly basis throughout the enrollment period (December 2012 to September 2015). These physicians were contacted to inform them of the study, and were provided with materials to invite their patients to participate. Secondary recruitment methods included referral by the surgeon or gastroenterologist at the time of diagnostic endoscopy, and advertisements at retailers of gluten-free products and in the newsletter of the Manitoba Chapter of the Canadian Celiac Association. The study was approved by the University of Manitoba Research Ethics Board.
Inclusion criteria for the Manitoba Coeliac Disease Cohort were: age greater than 16 years; HLA genotype associated with coeliac disease; and findings of villous atrophy (Marsh IIIa-IIIc[15 (link)]) on duodenal biopsy performed while consuming a gluten-containing diet. Persons unable to complete written surveys or oral interviews in English, unable to attend follow-up appointments, or who had been trying to follow a gluten-free diet for greater than six weeks prior to study entry were excluded.
Each participant completed an in-person interview and self-report survey at study entry (diagnosis of coeliac disease) and 6 months thereafter. These included items related to medical history, symptoms, diet and food choice. Symptom severity was assessed using the Celiac Symptom Index (CSI)[16 (link)]. The Celiac Diet Assessment Tool (CDAT)[17 (link)], a 7-item self-report measure with questions about symptoms and personal traits, and Gluten-Free Eating Assessment Tool (GF-EAT)[6 ], which also includes items related to gluten consumption during the past four weeks, were used to evaluate adherence to a gluten-free diet.
Suspected reactions to gluten were characterized using the REAC-G (Reactions Experienced After Consuming Gluten), a self-administered measure developed specifically for this study by a panel which included gastroenterologists, health psychologists, and persons with coeliac disease. The content was further revised by adding other potential symptoms following pretesting for readability and face validity by three members of the Canadian Celiac Association. The final version included 10 items related to the timing (3), quantity (2), symptoms (2), and circumstances (2) of the most recent gluten exposure and changes in these factors over time (1) (see Supplementary Material for full details).
Serum levels of anti-tissue transglutaminase antibodies (TTG) were determined using a standard ELISA kit (EUROIMMUN US, New Plains, New Jersey).
Data analysis was performed using RStudio Version 0.99.467[18 ] with R software version 3.1.2[19 ]. Descriptive statistics were used to characterize the group at baseline and the group who reported a symptomatic reaction to gluten. At baseline, those who experienced a symptom “often”, “very often” or “always” were considered symptomatic and those who “never” or “rarely” experienced the symptom were considered asymptomatic.
Silvester J.A., Graff L.A., Rigaux L., Walker J.R, & Duerksen D.R. (2016). Symptomatic suspected gluten exposure is common among patients with coeliac disease on a gluten-free diet. Alimentary pharmacology & therapeutics, 44(6), 612-619.
Publication 2016
anti-transglutaminase autoantibody Antibodies Atrophy Biopsy Celiac Disease Diagnosis Diet Duodenum Endoscopy, Gastrointestinal Enzyme-Linked Immunosorbent Assay Gastroenterologist Genotype Gluten Gluten-Free Diet Marshes Patients Physicians Serum Surgeons
4
Celiac Disease Serology and Biopsy
Cited 7 times
From among the 3,736 individuals, we randomly selected 120 identified through registry matching (EMA+: n = 40; AGA+: n = 40; TTGA+: n = 40), and requested their patient charts from the department or health care centre that requested the CD serology test, as well as from the department performing the small intestinal biopsy (usually departments of internal medicine/gastroenterology, surgery or pediatrics).
Using individual medical records (and when missing through phone contact with the responsible department/physician), we assessed the proportion of individuals who were correctly identified as having a macroscopically normal mucosa but positive CD serology, and who had never had a biopsy with inflammation or VA).
Again using medical records, we then examined symptoms, signs, laboratory measures, and the extent to which individuals had received information about gluten-free diet. This information was divided according to type of CD serology, and is presented both summarized and weighted according to the distribution of EMA+, TTGA+ and AGA+ among the 3,736 individuals from the complete data-set.
Ludvigsson J.F., Brandt L, & Montgomery S.M. (2009). Symptoms and signs in individuals with serology positive for celiac disease but normal mucosa. BMC Gastroenterology, 9, 57.
Publication 2009
Biopsy Gluten-Free Diet Inflammation Intestines, Small Mucous Membrane Operative Surgical Procedures Patients Physicians Tests, Serologic
5
Canadian Grocery Food Nutrition Database
Cited 6 times
Data acquisition occurred between May and September 2013, and was carried out in the Greater Toronto Area and Ottawa, Ontario, and Calgary, Alberta. Data were collected from major outlets of the four largest grocery chains in Canada (Loblaws, Metro, Sobeys, and Safeway), representing 75.4% of the grocery retail market share [29 ]. A Smartphone application was developed and used to scan and store the Universal Product Code (UPC), and to photograph all sides of food and beverage packages, and capture price. By systematically scanning the grocery store shelves, every food product with a Nutrition Facts table (NFt), including all available national and private label brands were collected. Seasonal products (e.g., eggnog, Easter chocolates), Natural Health Products (e.g., supplements), baby/toddler foods, and products that did not have a Canadian NFt (e.g., unpackaged fruits, vegetables) were excluded from the data collection. Food products sold at multiple retailers (such as national brand products) were captured only once. When multiple sizes of a product were available, only one size was sampled, but all flavours and varieties of a product were collected. Information collected for each product included the UPC, company, brand, price, NFt information, ingredients, container size, nutrient content claims, disease risk reduction claims, function claims, front of pack symbols, children’s marketing, other claims (e.g., organic, natural, and gluten-free), and date and location of sampling.
Bernstein J.T., Schermel A., Mills C.M, & L’Abbé M.R. (2016). Total and Free Sugar Content of Canadian Prepackaged Foods and Beverages. Nutrients, 8(9), 582.
Publication 2016
Beverages Child Chocolate Dietary Supplements Flavor Enhancers Food Fruit Gluten-Free Diet Infant Food Natural Products Nutrients SELL protein, human Vegetables

Most recents protocols related to «Gluten-Free Diet»

1
Gluten-free Composite Plant-MCT Flour
Not available on PMC !

Example 9

Gluten-free composite plant-MCT flour is made by replacing the gluten flour in Examples 1-7 with one or more gluten-free flours selected from oat flour, corn flour, white rice flour, buckwheat flour, sorghum flour, amaranth flour, teff flour, arrowroot flour, brown rice flour, chickpea flour, tapioca flour, cassava flour, tigernut flour, soy flour, potato flour, millet flour, or quinoa flour.

US11871773B1. Composite plant-MCT flour, method of manufacture, and food products made therefrom (2024-01-16). INNOVATIVE FLOURS, LLC [US]. Inventors: Gary Millet [US], Kylin Liao [CN].
Patent 2024
Amaranth Dye Buckwheat Chickpea Corn Flour Eragrostis Flour Food Gluten Gluten-Free Diet Manihot Manihot esculenta Maranta Millets Plants Potato Flour Quinoa Rice Flour Sorghum
2
Reduced Gluten and Carb Composite Flours
Not available on PMC !

Example 10

Reduced gluten and reduced carbohydrate composite plant-MCT flour is made by replacing 5-50% of the gluten flour in Examples 1-7 with one or more gluten-free and low carbohydrate flours selected from coconut flour, almond flour, peanut flour, sesame flour, sunflower seed flower, hazelnut flour, walnut flour, soy flour, chickpea flour, flaxseed (linseed) flour, fava bean flour, pumpkin seed flour, lupine flour, red lentil flour, or white bran flour.

US11871773B1. Composite plant-MCT flour, method of manufacture, and food products made therefrom (2024-01-16). INNOVATIVE FLOURS, LLC [US]. Inventors: Gary Millet [US], Kylin Liao [CN].
Patent 2024
Almond Flour Arachis hypogaea Carbohydrates Chickpea Coconut Flour Food Gluten Gluten-Free Diet Hazelnuts Helianthus annuus Juglans Lentils Lupinus Plants Pumpkins Sesame Vicia faba
3
Gluten-Free Composite Plant-MCT Flour
Not available on PMC !

Example 11

Gluten-free and low carbohydrate composite plant-MCT flour is made by replacing the flour in Examples 1-10 with one or more gluten-free and low carbohydrate flours selected from coconut flour, almond flour, peanut flour, sesame flour, sunflower seed flower, hazelnut flour, walnut flour, soy flour, chickpea flour, flaxseed (linseed) flour, fava bean flour, pumpkin seed flour, lupine flour, red lentil flour, or white bran flour.

US11871773B1. Composite plant-MCT flour, method of manufacture, and food products made therefrom (2024-01-16). INNOVATIVE FLOURS, LLC [US]. Inventors: Gary Millet [US], Kylin Liao [CN].
Patent 2024
Almond Flour Arachis hypogaea Carbohydrates Chickpea Coconut Flour Food Gluten-Free Diet Hazelnuts Helianthus annuus Juglans Lentils Lupinus Plants Pumpkins Sesame Vicia faba
4
Reduced Gluten Composite Flour
Not available on PMC !

Example 8

Reduced gluten composite plant-MCT flour is made by replacing 5-50% of the gluten flour in Examples 1-7 with one or more gluten-free flours selected from oat flour, corn flour, white rice flour, buckwheat flour, sorghum flour, amaranth flour, teff flour, arrowroot flour, brown rice flour, chickpea flour, tapioca flour, cassava flour, tigernut flour, soy flour, potato flour, millet flour, or quinoa flour.

US11871773B1. Composite plant-MCT flour, method of manufacture, and food products made therefrom (2024-01-16). INNOVATIVE FLOURS, LLC [US]. Inventors: Gary Millet [US], Kylin Liao [CN].
Patent 2024
Amaranth Dye Buckwheat Chickpea Corn Flour Eragrostis Flour Food Gluten Gluten-Free Diet Manihot Manihot esculenta Maranta Millets Plants Potato Flour Quinoa Rice Flour Sorghum
5
H. pylori Mimicry of Celiac Disease
This study was designed to explain the probable involvement of H. pylori in mimicking celiac disease pathology and, as a result, influencing screening test results. To do so, we selected three groups of children between 2 and 18 years old were referred to Mofid children hospital and Children’s Medical Center, tertiary medical centers of children in Tehran/Iran for diagnosis of CD.
IgA EMA was measured by an indirect immunofluorescence method ((EmA Kit Biosystems, Genova, Italy). IgA anti TTG was measured by ELISA (ImmuLisa, Immco, USA).
Patients referred for upper endoscopy for confirming diagnosis of CD. Five biopsy samples (4 from D2 and 1 from bulb) were sent. In addition four gastric biopsy samples were sent (2 from antrum, 1 from cardia and 1 from body). Two pathologists expert in the field have reviewed the tissues.
The two groups who had moderate to heavy colonization with H.pylori infection according to gastric biopsy results. These patients introduced to ethics committee of research institute for children health. After written informed consent they referred to pediatric gastroenterologist for treatment of H pylori infection. Two weeks course of treatment with antibiotics and proton pomp inhibitor was performed. All patients had examined for H.pylori infection eradication by stool antigen 6 weeks later. During these 6 weeks, the patients were not subjected to a gluten-free diet, but after the 6th week and re-examination and eradication of H.pylori infection in the stool, based on the confirmation of celiac disease, they were subjected to the desired diet. Furthermore, the anti-endomysial antibody (EMA-IgA(mg/dL)) test was checked before and after therapy in the first group. This test was also performed in the third group of celiac patients with negative H. pylori, but not in the second group of non-celiac patients with positive H.pylori because it was not scientifically necessary.
Rohani P., Zadeh M.M., Alimadadi H, & Sohouli M.H. (2023). Effect of helicobacter pylori infection eradication on serum level of anti-tissue transglutaminase in children with celiac disease. BMC Pediatrics, 23, 116.
Publication 2023
Antibiotics Antibodies, Anti-Idiotypic Antigens Antral Biopsy Cardia Celiac Disease Child Children's Health Diagnosis Diet Endoscopy Enzyme-Linked Immunosorbent Assay Ethics Committees, Research Feces Fluorescent Antibody Technique, Indirect Gastroenterologist Gluten-Free Diet Helicobacter pylori Human Body IgA anti-tissue transglutaminase autoantibodies Infection Medulla Oblongata Pathologists Patients Protons Stomach Therapeutics Tissues

Top products related to «Gluten-Free Diet»

1
Sodium hydroxide (naoh) by Merck Group
Sourced in Germany, United States, India, United Kingdom, Italy, China, Spain, France, Australia, Canada, Poland, Switzerland, Singapore, Belgium, Sao Tome and Principe, Ireland, Sweden, Brazil, Israel, Mexico, Macao, Chile, Japan, Hungary, Malaysia, Denmark, Portugal, Indonesia, Netherlands, Czechia, Finland, Austria, Romania, Pakistan, Cameroon, Egypt, Greece, Bulgaria, Norway, Colombia, New Zealand, Lithuania
Sodium hydroxide is a chemical compound with the formula NaOH. It is a white, odorless, crystalline solid that is highly soluble in water and is a strong base. It is commonly used in various laboratory applications as a reagent.
2
Mcr 301 by Anton Paar
Sourced in Austria, Germany, United States, Japan, Switzerland, Belgium
The MCR 301 is a rheometer, a device used to measure the flow and deformation properties of materials. It is designed to perform rotational and oscillatory measurements on a wide range of samples, including liquids, pastes, and gels.
3
Gliadin by Merck Group
Sourced in United States
Gliadin is a laboratory equipment product offered by Merck Group. It is a key protein component found in wheat gluten. Gliadin serves as a reference standard for analytical testing and research applications.
4
Aqualab 4te by METER Group
Sourced in United States, Brazil, Spain
The Aqualab 4TE is a laboratory instrument designed for precise water activity measurement. It utilizes chilled-mirror dew point technology to determine the equilibrium relative humidity (eRH) of a sample, which is then used to calculate the water activity. The Aqualab 4TE can accommodate a wide range of sample types and provides accurate and reliable results.
5
Accupyc 2 1340 by Micromeritics
Sourced in United States, United Kingdom, Germany
The AccuPyc II 1340 is a gas displacement pycnometer that measures the true volume and density of solid materials. It uses helium gas to accurately determine the volume of a sample, which is then used to calculate its density.
6
Lc 20at pump by Shimadzu
Sourced in Japan, United States, Australia
The LC-20AT pump is a high-performance liquid chromatography (HPLC) pump designed for a wide range of applications. It delivers a stable and accurate flow rate, ensuring consistent and reliable performance in analytical procedures.
7
Celikey by Thermo Fisher Scientific
Sourced in Germany
Celikey is a diagnostic kit used to detect and measure antibodies related to celiac disease. The kit utilizes an enzyme-linked immunosorbent assay (ELISA) method to quantify the levels of specific antibodies in a patient's blood sample. Celikey provides a reliable tool for the diagnosis and monitoring of celiac disease.
8
Cholera toxin by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, France, China, Canada, Macao, Sao Tome and Principe, Australia, Israel, Switzerland, Spain, Japan
Cholera toxin is a bacterial protein produced by the bacterium Vibrio cholerae. It has a well-documented function as a potent activator of the adenylate cyclase enzyme, leading to increased levels of cyclic AMP (cAMP) in target cells. This property makes cholera toxin a valuable tool in various areas of biological research, such as cell signaling studies and the investigation of cellular regulatory mechanisms.
9
Feso4 by Merck Group
Sourced in United States, Germany, Italy, China, Poland, Belgium
FeSO4 is an inorganic compound that serves as a source of iron (Fe) and sulfate (SO4) ions. It is a crystalline solid that is typically used in various industrial and laboratory applications.

More about "Gluten-Free Diet"

The gluten-free diet, also known as the GF diet, is a dietary regimen designed to eliminate the consumption of gluten, a protein found in wheat, barley, and rye.
This specialized diet is primarily used to manage celiac disease, a condition where the immune system reacts abnormally to gluten, causing damage to the small intestines.
Adhering to a gluten-free diet can help reduce symptoms and prevent long-term complications in those with celiac disease.
The GF diet may also be prescribed for non-celiac gluten sensitivity, a condition where individuals experience gastrointestinal distress after consuming gluten-containing foods.
Carefully following a gluten-free diet, which requires avoiding breads, pastas, cereals, and many processed foods, is essential for maintaining intestinal health and nutrient absorption in those with gluten-related disorders.
Researchers can explore the latest advancements in gluten-free research using tools like PubCompare.ai, an AI-driven platform that helps locate the best protocols from literature, pre-prints, and patents.
This platform can enhance the reproducibility of gluten-free studies and assist in finding the most effective gluten-free products through its advanced search and comparison capabilities.
Beyond the dietary aspects, the gluten-free lifestyle may also involve the use of sodium hydroxide (NaOH) for the production of gluten-free baked goods, the utilization of MCR 301 for rapid moisture content analysis, and the study of gliadin, a component of gluten, using instruments like the Aqualab 4TE and AccuPyc II 1340.
Additionally, the Celikey test may be employed to detect celiac disease, and the cholera toxin can be used as a reference standard in gluten-free research.
Researchers can also explore the use of ferrous sulfate (FeSO4) in the development of gluten-free products.